Article: Cantab Pharmaceuticals Reports Fourth Quarter Results

CAMBRIDGE, England, March 19 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY) today announced financial results for the fourth quarter and year ended December 31, 1996.

Revenues for the fourth quarter of 1996 were 50,000 Pounds Sterling, compared to 83,000 pounds for the same period in 1995. Revenues in 1996 were 3.1 million pounds, compared to 755,000 pounds in 1995. Most of the 1996 revenues was 3 million pounds in license fees paid by SmithKline Beecham Biologicals (SBBio) in July 1996, with an additional 115,000 pounds received under Cantab's existing research agreement with Pfizer Animal Healthcare Group. In 1995, Cantab's revenues came ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!